Cell augmentation strategies for cardiac stem cell therapies

Myocardial infarction (MI) has been the primary cause of death in developed countries, resulting in a major psychological and financial burden for society. Current treatments for acute MI are directed toward rapid restoration of perfusion to limit damage to the myocardium, rather than promoting tiss...

Full description

Saved in:
Bibliographic Details
Published in:Stem cells translational medicine 2021-06, Vol.10 (6), p.855-866
Main Authors: Cruz‐Samperio, Raquel, Jordan, Millie, Perriman, Adam
Format: Article
Language:English
Subjects:
Angiogenesis
Bone marrow
cardiac
Cardiac function
Cardiomyocytes
Cardiovascular disease
Cell membranes
cell migration
Cell therapy
cellular therapy
clinical translation
Clinical trials
Concise Review
Cytokines
Engraftment
Extracellular matrix
Heart
Humans
Immobilization
Interfaces
Medical prognosis
Mortality
Multipotent Stem Cells - cytology
Muscle contraction
Myocardial infarction
Myocardial Infarction - physiopathology
Myocardium
Myocardium - cytology
Perfusion
Regeneration
Retention
Scars
Stem Cell Transplantation - methods
Stem cells
Tissue engineering
Wound Healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myocardial infarction (MI) has been the primary cause of death in developed countries, resulting in a major psychological and financial burden for society. Current treatments for acute MI are directed toward rapid restoration of perfusion to limit damage to the myocardium, rather than promoting tissue regeneration and subsequent contractile function recovery. Regenerative cell therapies (CTs), in particular those using multipotent stem cells (SCs), are in the spotlight for treatment post‐MI. Unfortunately, the efficacy of CTs is somewhat limited by their poor long‐term viability, homing, and engraftment to the myocardium. In response, a range of novel SC‐based technologies are in development to provide additional cellular modalities, bringing CTs a step closer to the clinic. In this review, the current landscape of emerging CTs and their augmentation strategies for the treatment post‐MI are discussed. In doing so, we highlight recent advances in cell membrane reengineering via genetic modifications, recombinant protein immobilization, and the utilization of soft biomimetic scaffold interfaces. In this concise review, the landscape of emerging cell augmentation strategies for cardiovascular stem cell therapies are discussed. In particular, we highlight recent advances in cell membrane re‐engineering via genetic modifications, recombinant protein immobilization, and the utilization of soft biomimetic scaffold interfaces.
ISSN:2157-6564
2157-6580
DOI:10.1002/sctm.20-0489